Novel risk factors for stroke: Homocysteine, inflammation, and infection

Current Atherosclerosis Reports

Volumn 2, Issue 2, 2000, Pages 110-114

  Goldstein, Larry B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Azithromycin; Homocysteine; Homocysteine Level; Ischemic Stroke; Plasma Homocysteine

Indexed keywords

HOMOCYSTEINE;

BLOOD; CEREBROVASCULAR ACCIDENT; HUMAN; INFECTION; INFLAMMATION; REVIEW; RISK FACTOR;

CEREBROVASCULAR ACCIDENT; HOMOCYSTEINE; HUMANS; INFECTION; INFLAMMATION; RISK FACTORS;

EID: 0034157074     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-000-0104-2     Document Type: Article

References (54)

1. Sacco RL, Benjamin EJ, Broderick JP, et al.: American Heart Association Prevention Conference IV: Risk Factors. Stroke 1997, 28: 1507–1517.
2. Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In The Metabolic Basis of Inherited Disease, 6 edn. Edited by Schriver C, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1989:693–734.
3. Mudd SH, Skovby F, Levy HL, et al.: The natural history of homocystienuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985, 37:1–31.
4. Wall RT, Harlan JM, Harker LA, Striker GE: Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980, 18:113–121. DOI: 10.1016/0049-3848(80)90175-9
5. Rodgers GM, Kane WH: Activation of endogenous factor V by homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986, 77:1909–1916.
6. Rodgers GM, Conn MT: Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990, 75:895–901.
7. Boers GHJ, Smals AGH, Trijbels FJM, et al.: Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985, 313:709–715. DOI: 10.1056/NEJM198509193131201
8. Brattstrom L, Lindgren A: Hyperhomocysteinemia as a risk factor for stroke. Neurol Res 1992, 14:81–84. DOI: 10.1016/0168-0102(92)90085-Q
9. Sacco RL, Roberts JK, Jacobs BS: Homocysteine as a risk factor for ischemic stroke: an epidemiological story in evolution. Neuroepidemiology 1998, 17:167–173. DOI: 10.1159/000026169
10. Lindgren A, Brattstrom L, Norrving B, et al.: Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995, 26:795–800.
11. Ueland PM, Refsum H, Brattström L: Plasma homocysteine and cardiovascular disease. In Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. Edited by Francis Jr RB. New York: Marcel Dekker, Inc.; 1992:183–236.
12. Giles WH, Croft JB, Greenlund KJ, et al.: Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey, 1988–1994. Stroke 1998, 29:2473–2477.
13. Yoo JH, Chung CS, Kang SS: Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998, 29:2478–2483.
14. Robinson K, Arheart K, Refsum H, et al.: Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998, 97: 437–443.
15. Brattstrom L, Israelsson B, Norrving B, et al.: Impaired homocyst(e)ine metabolism in early onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis 1990, 81:51–60. DOI: 10.1016/0021-9150(90)90058-Q
16. Coull BM, Malinow MR, Beamer N, et al.: Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990, 21:572–576.
17. Verhoef P, Hennekens CH, Malinow RM, et al.: A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994, 25:1924–1930.
18. Bots ML, Launer LJ, Lindemans J, et al.: Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. Arch Intern Med 1999, 159:38–44. DOI: 10.1001/archinte.159.1.38
19. van Beynum IM, Smeitink JAM, der Heijer M, et al.: Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation 1999, 99:2070–2072.
20. Kang S-S, Wong PWK, Susmano A, et al.: Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991, 48:536–545.
21. Frosst P, Blom HJ, Milos R, et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995, 10:111–113. DOI: 10.1038/ng0595-111
22. Spence JD, Malinow MR, Barnett PA, et al.: Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke 1999, 30:969–973.
23. Markus HS, Ali N, Swaminathan R, et al.: A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997, 28:1739–1743.
24. Lalouschek W, Aull S, Serles W, et al.: C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. Thrombosis Research 1999, 93:61–69. DOI: 10.1016/S0049-3848(98)00154-6
25. Stabler SP, Marcell PD, Podell ER, et al.: Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatographymass spectrometry. J Clin Invest 1988, 81:466–474. DOI: 10.1172/JCI113343
26. 12 deficiency than in heterozygosity for homocystinuria due to cystathionine β-synthase deficiency. Metabolism 1988, 37:175–178. DOI: 10.1016/S0026-0495(98)90014-2
27. Selhub J, Jacques PF, Wilson PWF, et al.: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993, 270:2693–2698. DOI: 10.1001/jama.270.22.2693
28. Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk factor for vascular disease. JAMA 1997, 277:1775–1781. DOI: 10.1001/jama.277.22.1775
29. Lindsberg PJ, Carpén O, Paetau A, et al.: Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation 1996, 94:939–945.
30. Yanaka K, Spellman SR, McCarthy JB, et al.: Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. I. Protective mechanism. J Neurosurg 1996, 85:1102–1107. DOI: 10.3171/jns.1996.85.6.1102
31. Hayward NJ, Elliott PJ, Sawyer SD, et al.: Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat. Exper Neurol 1996, 139:188–202. DOI: 10.1006/exnr.1996.0093
32. Hess DC, Zhao W, Carroll J, et al.: Increased expression of ICAM-1 during reoxygenation in brain endothelial cells. Stroke 1994, 25:1463–1467.
33. Pantoni L, Sarti C, Inzitari D: Cytokines and cell adhesion molecules in cerebral ischemia. Experimental bases and therapeutic perspectives. Arterioscler Thromb Vasc Biol 1998, 18:503–513.
34. Kim JS: Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996, 137:69–78. DOI: 10.1016/0022-510X(95)00338-3
35. Muir KW, Weir CJ, Alwan W, et al.: C-reactive protein and outcome after ischemic stroke. Stroke 1999, 30:981–985.
36. Mendall MA, Patel PBL, Strachan D, Northfield TC: C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996, 312:1061–1065.
37. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007–2011.
38. Ridker PM, Buring JE, Shih J, et al.: Prospective study of C-reactive protein and the risk of future cardiovascular events among healthy women. Circulation 1998, 98:731–733.
39. Ridker RM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979. DOI: 10.1056/NEJM199704033361401
40. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989, 321:129–135. DOI: 10.1056/NEJM198907203210301
41. Bova IY, Bornstein NM, Korczyn AD: Acute infection as a risk factor for ischemic stroke. Stroke 1996, 27:2204–2206.
42. Bornstein NM, Bova IY, Korczyn AD: Infections as triggering factors for ischemic stroke. Neurology 1997, 49 (suppl 4): S45-S46.
43. Grau AJ: Infection, inflammation, and cerebrovascular ischemia. Neurology 1997, 49 (suppl 4):S47-S51.
44. Grau AJ, Brandt T, Buggle F, et al.: Association of cervical artery dissection with recent infection. Arch Neurol 1999, 56:851–856. DOI: 10.1001/archneur.56.7.851
45. Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998, 26:719–734.
46. Macko RF, Ameriso SF, Gruber A, et al.: Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke 1996, 27:2005–2011.
47. Grayston JT, Kuo C-C, Coulson AS, et al.: Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995, 92:3397–3400.
48. Johnston SC, Messina LM, Browner WS, et al.: Chlamydia pneumoniae and carotid atherosclerosis. Ann Neurol 1999, 49:479–450.
49. Wimmer ML, Sandmann-Strupp R, Saikku P, Haberl RL: Association of chlamydial infection with cerebrovascular disease. Stroke 1996, 27:2207–2210.
50. Cook PJ, Honeybourne D, Lip GY, et al.: Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke 1998, 29: 404–410.
51. Fagerberg B, Gnarpe J, Gnarpe H, et al. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease. A prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999, 30:299–305.
52. Glader CA, Stegmayr B, Boman J, et al.: Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in northern Sweden. Stroke 1999, 20:2013–2018.
53. Gupta S, Leatham EW, Carrington D, et al.: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997, 96:404–407.
54. Anderson JL, Muhlestein JB, Carlquist J, et al.: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999, 99:1540–1547.